Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

78 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
First-dose effects of fingolimod after switching from injectable therapies in the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis.
Hughes B, Cascione M, Freedman MS, Agius M, Kantor D, Gudesblatt M, Goldstick LP, Agashivala N, Schofield L, McCague K, Hashmonay R, Barbato L; EPOC study investigators. Hughes B, et al. Among authors: gudesblatt m. Mult Scler Relat Disord. 2014 Sep;3(5):620-8. doi: 10.1016/j.msard.2014.06.006. Epub 2014 Jul 3. Mult Scler Relat Disord. 2014. PMID: 26265274 Clinical Trial.
Safety and efficacy of ADS-5102 (amantadine) extended release capsules to improve walking in multiple sclerosis: A randomized, placebo-controlled, phase 2 trial.
Cohen JA, Hunter SF, Brown TR, Gudesblatt M, Thrower BW, Llorens L, Souza-Prien CJ, Ruby AE, Chernoff DN, Patni R. Cohen JA, et al. Among authors: gudesblatt m. Mult Scler. 2019 Apr;25(4):601-609. doi: 10.1177/1352458518754716. Epub 2018 Jan 25. Mult Scler. 2019. PMID: 29368539 Free article. Clinical Trial.
Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study.
Naismith RT, Wolinsky JS, Wundes A, LaGanke C, Arnold DL, Obradovic D, Freedman MS, Gudesblatt M, Ziemssen T, Kandinov B, Bidollari I, Lopez-Bresnahan M, Nangia N, Rezendes D, Yang L, Chen H, Liu S, Hanna J, Miller C, Leigh-Pemberton R. Naismith RT, et al. Among authors: gudesblatt m. Mult Scler. 2020 Nov;26(13):1729-1739. doi: 10.1177/1352458519881761. Epub 2019 Nov 4. Mult Scler. 2020. PMID: 31680631 Free PMC article.
Effect of dimethyl fumarate on lymphocyte subsets in patients with relapsing multiple sclerosis.
Buckle G, Bandari D, Greenstein J, Gudesblatt M, Khatri B, Kita M, Repovic P, Riser E, Weinstock-Guttman B, Thrower B, Loring S, Riester K, Everage N, Prada C, Koulinska I, Mann M. Buckle G, et al. Among authors: gudesblatt m. Mult Scler J Exp Transl Clin. 2020 Apr 29;6(2):2055217320918619. doi: 10.1177/2055217320918619. eCollection 2020 Apr-Jun. Mult Scler J Exp Transl Clin. 2020. PMID: 32440353 Free PMC article.
Variability of objective gait measures across the expanded disability status scale in people living with multiple sclerosis: A cross-sectional retrospective analysis.
Zanotto T, Sosnoff JJ, Ofori E, Golan D, Zarif M, Bumstead B, Buhse M, Kaczmarek O, Wilken J, Muratori L, Covey TJ, Gudesblatt M. Zanotto T, et al. Among authors: gudesblatt m. Mult Scler Relat Disord. 2022 Mar;59:103645. doi: 10.1016/j.msard.2022.103645. Epub 2022 Jan 30. Mult Scler Relat Disord. 2022. PMID: 35124304
The relationship between cognitive impairment, cognitive fatigue, and visual evoked potential latency in people with multiple sclerosis.
Covey TJ, Golan D, Doniger GM, Sergott R, Zarif M, Bumstead B, Buhse M, Kaczmarek O, Mebrahtu S, Bergmann C, Wilken J, Gudesblatt M. Covey TJ, et al. Among authors: gudesblatt m. Mult Scler Relat Disord. 2022 Jan;57:103349. doi: 10.1016/j.msard.2021.103349. Epub 2021 Oct 29. Mult Scler Relat Disord. 2022. PMID: 35158458
Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 Study.
Wray S, Then Bergh F, Wundes A, Arnold DL, Drulovic J, Jasinska E, Bowen JD, Negroski D, Naismith RT, Hunter SF, Gudesblatt M, Chen H, Lyons J, Shankar SL, Kapadia S, Mendoza JP, Singer BA. Wray S, et al. Among authors: gudesblatt m. Adv Ther. 2022 Apr;39(4):1810-1831. doi: 10.1007/s12325-022-02068-7. Epub 2022 Feb 24. Adv Ther. 2022. PMID: 35211872 Free PMC article. Clinical Trial.
78 results